XenoPort Receives FDA Approval For Horizant (XNPT)

XenoPort Inc XNPT stock saw a 65% surge in share prices to $10.56 following Food and Drug Administration (FDA) approval on Wednesday for Horizant, an extended-release tablet for the treatment of Restless Legs Syndrome. Horizant is converted into gabapentin once it is absorbed in the body. Gabapentin binds to a specific type of calcium channel eliminating the effects of Restless Leg Syndrome. The exact mechanism of action is unknown, but it has been shown that alternate gabapentin products do not have the same effects on Restless Leg Syndrome because of differing pharmacokinetic profiles. Horizant is XenoPort's first product to receive approval from the FDA.